Sanofi has announced that Paul Hudson, CEO, will be in attendance at the 44^th annual JP Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026, at 9:45 am PST. The company has currently not revealed its presentation plans.

2025

2025 became the year Sanofi invested heavily into its pipeline visibility. Throughout the year the company emphasized late-stage drug prospects as key drivers to sustaining growth beyond Dupixent, the company’s largest growth driver, highlighting assets in immunology, respiratory disease, and vaccines. For more background, read Pharm Exec’s cover profile of Hudson for the September 2025 issue here.

The 2025 messaging has resonated in varying ranges with investors, contributing to shifts in analyst sentiment as expectations around timing and probability of success evolved.

At the last JP Morgan conference, Sanofi positioned its R&D engine as the company’s most important long-term lever. Meanwhile, company leadership continued to underscore changes made over the past several years, including improving decision-making, accelerating development timelines, and concentrating capital on programs with the clearest paths to differentiation.¹

Sanofi’s plan, as suggested by executives, is to build a portfolio capable of collectively absorbing the eventual sales erosion of Dupixent from patent expirations, rather than attempt to replace the immunology blockbuster with a single successor.

That framing was reflected in mixed analyst reactions during 2025. JP Morgan itself upgraded Sanofi to “overweight,” pointing to the organization’s late-stage pipeline depth and improving execution.

While others urged caution, citing the long runway to commercialization for many assets and the sheer magnitude of Dupixent’s contribution today, the tension between promise and proof became a defining feature of Sanofi’s 2025 narrative.

Importantly, the company continued to emphasize that it has time, with Dupixent exclusivity extending into the early 2030s. Sanofi, also via several key acquisitions and partnerships announced this year, has positioned the next several years as a window for disciplined buildup rather than rushed transformation.

2024

In 2024, Sanofi delivered solid financial results, reinforcing the durability of its core franchises while also sharpening focus on what came next.

Throughout the year, Dupixent remained the company’s primary growth engine, continuing to expand across indications and geographies, and underscoring both the strength and the concentration of Sanofi’s revenue base.

Sanofi rather than shy away from that reality, increasingly acknowledging that Dupixent’s expected loss of exclusivity between 2031 and 2033 is not a distant abstraction, and began constructing a plan for its pipeline’s future.

Beyond Dupixent, 2024 highlighted incremental progress in Sanofi’s broader pipeline portfolio. Two of the biggest contributors, vaccines and specialty care, contributed steady performance while the company continued to streamline its footprint following prior divestments.

The year was marked by discipline rather than expansion, including maintaining margins, prioritizing late-stage assets, and reinforcing investor confidence of Sanofi’s transformation into a more focused biopharma.

Equity research reflected that balance with some analysts characterizing Sanofi as undervalued relative to its late-stage pipeline potential, pointing to a growing number of Phase II and III programs that hold the potential to diversify revenue well before Dupixent faces biosimilar competition.

Still, the market’s view remained cautious, reflecting the scale of the eventual exclusivity cliff.

As mentioned, Dupixent’s expected loss of exclusivity between 2031 and 2033 looms as the defining strategic inflection point for Sanofi, shaping decisions well before competitive pressure materializes.

The drug has delivered years of expansion across multiple indications, yet its eventual exposure to biosimilar competition represents a revenue risk that cannot be offset by incremental growth alone. Sanofi has consistently framed the timeline as an opportunity rather than a cliff, using the remaining years of exclusivity to scale adjacent indications, maximize lifecycle value, and, advance a diversified late-stage pipeline capable of absorbing the product’s gradual decline.

For investors, the key question is not whether Dupixent remains a powerful asset, but whether Sanofi can translate late-stage promise into a credible growth bridge well before 2031.

Sources

1. 43rd Annual J.P. Morgan Healthcare Conference Sanofi January 14, 2025 https://www.sanofi.com/assets/dotcom/content-app/events/broker-conference/2025/43rd-annual-jp-morgan-healthcare/Sanofi_JPMorgan_01_14_2025.pdf
2. Q3: Continued Sales and Earnings Progress Sanofi October 24, 2025 https://www.sanofi.com/en/media-room/press-releases/2025/2025-10-24-05-30-00-3172594
3. Sanofi: Undervalued 2026 Pipeline, And Solid Results (Rating Upgrade) Seeking Alpha October 5, 2025 https://seekingalpha.com/article/4827905-sanofi-undervalued-2026-pipeline-and-solid-results-rating-upgrade
4. Fourth Quarter & Full Year 2024 Results Sanofi Accessed December 23, 2025 https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/q4-results-2024
5. Sanofi upgraded to “overweight” by J.P. Morgan on late-stage drug prospects Investing.com August 8, 2025 https://www.investing.com/news/stock-market-news/sanofi-upgraded-to-overweight-by-jp-morgan-on-latestage-drug-prospects-4178982
6. 44rd Annual J.P. Morgan Healthcare Sanofi Accessed December 23, 2025 https://www.sanofi.com/en/investors/broker-conferences/44rd-annual-jp-morgan-healthcare